Title
Fatty Acid binding protein 7 is a molecular marker in adenoid cystic carcinoma of the salivary glands: implications for clinical significance.

Permalink
https://escholarship.org/uc/item/1430536f

Journal
Translational oncology, 7(6)

ISSN
1936-5233

Authors
Phuchareon, Janyaporn
Overdevest, Jonathan B
McCormick, Frank
et al.

Publication Date
2014-12-01

DOI
10.1016/j.tranon.2014.10.003

Peer reviewed
Fatty Acid Binding Protein 7 Is a Molecular Marker in Adenoid Cystic Carcinoma of the Salivary Glands: Implications for Clinical Significance1,2

Abstract
Adenoid cystic carcinoma (ACC) is an aggressive malignant neoplasm of the salivary glands. Its diagnosis is difficult due to overlapping features with other salivary tumors. Gene expression analysis may complement traditional diagnostic methods. We searched gene expression patterns in the Gene Expression Omnibus (GEO) database and in our tumor and normal samples. The biologic and prognostic potential of the identified genes was analyzed. The GEO data set of primary xenografted ACCs revealed that expression of five genes, engrailed homeobox 1 (EN1), fatty acid binding protein 7 (FABP7), hemoglobin epsilon 1, MYB, and versican (VCAN), was dramatically increased. mRNA expression of EN1, FABP7, MYB, and VCAN distinguished our sporadic ACCs from normal tissues and benign tumors. FABP7 expression appeared to be regulated differently from EN1 and MYB and was crossly correlated with poor prognosis in our ACC cohort. Immunohistochemistry showed that FABP7 protein was predominantly expressed in the nucleus of myoepithelial cells of both tubular and cribriform subtypes. In contrast, in the solid subtype, which is often associated with a lower survival rate, FABP7 protein was uniformly expressed in cancerous cells. One case with cribriform architecture and the highest level of FABP7 mRNA showed strong FABP7 staining in both duct-type epithelial and myoepithelial cells, suggesting that diffuse expression of FABP7 protein might be related to aggressive tumor behavior and poor prognosis. We propose FABP7 as a novel biomarker in ACC. The molecule may be useful in diagnosis and for identifying more effective therapies targeting this protein or upstream molecules that regulate it.

Introduction
Adenoid cystic carcinoma (ACC) is a high-grade malignant neoplasm of the salivary glands with unique histology and variable clinical behavior [1–5]. ACC has a propensity to metastasize extensively and the long-term prognosis is not favorable. Distant metastases can develop despite local and regional tumor control and can be delayed, sometimes occurring 10 to 20 years after diagnosis. Unfortunately, therapeutic options for ACC are limited and usually consist of surgery and postoperative radiation therapy. These interventions, however, have failed to affect long-term outcomes in ACC.

The diagnosis of ACC is another challenge. Existing imaging methods, including ultrasonography, computed tomography, magnetic resonance imaging (MRI), and radionuclide scanning, do not
provide a definitive diagnosis [6,7]. Evaluation of fine needle aspiration biopsy material is not always reliable diagnostically, due to the overlapping microscopic features between ACC and other salivary gland neoplasms [8–10]. Accurate diagnosis, however, is important to guide proper surgery and adjuvant treatment [1–5]. Gene expression analysis will likely be an important complement to traditional diagnostic methods in the diagnosis of ACC [11,12]. As an example, immunohistochemical staining for c-Kit is often used in conjunction with histology to aid in diagnosis of ACC. c-Kit, a proto-oncogene, is overexpressed in almost all ACCs but seldom increased in other head and neck tumors [3–5].

Other potential diagnostic markers for ACC have been reported. For example, 6q21 chromosomal translocations involving genes encoding transcription factors MYB and nuclear factor IIB have been found in roughly half of ACCs [13,14]. In addition, a gene expression profile of ACC found elevated expression of a variety of extracellular matrix gene products, including versican (VCAN) [15]. More recently, engrailed homebox 1 (EN1) was reported as a biomarker for ACC [16]. However, it is not clear whether these molecules were increased specifically in ACC or to what extent they contribute to its malignant growth, metastasis, and prognosis. The objective of this study was to identify a diagnostic molecular marker for ACC, which would be a predictor of the prognosis and a possible therapeutic target. With a biomarker, advances in ACC management may be possible [2].

We searched the Gene Expression Omnibus (GEO) database for potential diagnostic biomarkers of ACC. Expression microarrays of 11 primary xenografted ACCs and 3 normal salivary gland tissues and were the five most elevated genes [17]. Similar primary xenografted ACCs revealed that levels of potential diagnostic biomarkers of ACC. Expression microarrays of 11 detectable with our extracts. We also observed a correlation between cell adenomas (BCAs) and pleomorphic adenomas (PAs).

ACCs from normal salivary tissues and benign tumors, including basal were considerably elevated. Expression of these genes distinguished ACC based on its subcellular distribution and cell type more effective therapeutic options. We discuss a potential role of FABP7 in predict prognosis, monitor patients in remission, and is a starting point for diagnose ACC, aid tumor screening, help delineate surgical margins, and solid (1). In the BCAs, all four tumors occurred in women and arose in the middle ear with a median age of 60 years (range, 40–73 years). In the PAs, three tumors occurred in women. Median age at presentation was 58 years (range, 33–91 years). Tumors arose at the following sites: maxillary sinus (nine tumors), submandibular gland (six tumors), parotid gland (five tumors), sublingual gland (two tumors), and one each in the nasal cavity, mandibular mucosa, nasopharynx, base of tongue, and tongue. Tumors were classified by morphologic subtype: tubular (4 cases), cribriform (3), solid (1), combined cribriform and tubular (2), and solid and tubular (8), and combined cribriform and solid (1). In the BCAs, all four tumors occurred in women and arose in the parotid gland. Median age at presentation was 60 years (range, 40–73 years). In the PAs, three tumors occurred in women. Median age at presentation was 46 years (range, 20–67 years), and four tumors arose in the parotid gland with one in the submandibular gland. Two of five normal salivary tissue specimens were from women. Median age at presentation was 62 years (range, 33–91 years). Three samples represented tissue excised from the submandibular gland; two were from the parotid gland.

**Materials and Methods**

**Tumor and Normal Samples**

We obtained 27 ACCs, 4 BCAs, and 5 PAs, as well as 5 normal salivary tissue samples from the University of California, San Francisco (UCSF) Anatomic Pathology archives. Institutional review board (IRB) approval was obtained and UCSF guidelines for handling human tissue were followed. Representative normal salivary tissues were additionally chosen from ACC patients whose tumor samples were included in this study. Slides were reviewed to determine tissue suitability for gene expression analysis.

**TaqMan Quantitative Polymerase Chain Reaction Assay**

Gene expression was analyzed in triplicate with TaqMan quantitative polymerase chain reaction (qPCR). Total RNA was isolated using RNAeasy kits (Qiagen, Valencia, CA) from formalin-fixed, paraffin-embedded tumor tissue sections composed of at least 70% tumor cells. cDNA from 500 ng of total RNA was synthesized with an RT first-strand kit (Life Technologies, Carlsbad, CA). cDNA (5 ng) was mixed with transcriptase (RT) qPCR master mixes, and aliquots were placed with gene-specific primer sets. The following TaqMan assays (all from Life Technologies) were used: EN1 (Hs00154977_m1), FABP7 (Hs00361426_m1), HBE1 (Hs00362216_m1), VCAN (Hs00171642_m1), and MYB (Hs00920554_m1). Expression levels normalized to endogenous glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were determined by real-time PCR and analyzed at the UCSF Comprehensive Cancer Center Genome Analysis Core Facility. Fold changes in gene expression were calculated as the ratio of expression in each sample to average expression in controls. Statistical analyses and graphs were made using Microsoft Office Excel and XLSTAT (Addinsoft, New York, NY). Statistical comparisons between data sets were made with two-tailed Student’s t tests and log rank tests, and P < 0.05 was considered significant.

**Immunohistochemistry**

Immunohistochemistry was performed on unstained sections using antibody-based staining kits for FABP7 (AF3166; R&D Systems, Minneapolis, MN) or goat isotype control (AB-108-C; R&D Systems) at the UCSF Comprehensive Cancer Center Immunohistochemistry and Molecular Pathology Core Facility. The detailed procedure for staining has been described [3]. FABP7 staining was visually estimated by a head and neck pathologist (A.v.Z.).

**Results**

**Tumor Characteristics**

A total of 41 samples of salivary tissues from the UCSF archives was included in this study: 27 cases of ACC, 4 BCAs, 5 PAs, and 5 normal salivary gland samples. We included BCAs and PAs in the study because the microscopic features of these tumors often overlap with those of ACC, and distinguishing them is important for appropriate management of patients with salivary gland tumors. All tumors had arisen sporadically. Sixteen ACC tumors occurred in women. The median age at presentation was 58 years (range, 33–91 years). Tumors arose at the following sites: maxillary sinus (nine tumors), submandibular gland (six tumors), parotid gland (five tumors), sublingual gland (two tumors), and one each in the nasal cavity, mandibular mucosa, nasopharynx, base of tongue, and tongue. Tumors were classified by morphologic subtype: tubular (4 cases), cribriform (3), solid (1), combined cribriform and tubular (10), combined solid and tubular (8), and combined cribriform and solid (1). In the BCAs, all four tumors occurred in women and arose in the parotid gland. Median age at presentation was 60 years (range, 40–73 years). In the PAs, three tumors occurred in women. Median age at presentation was 46 years (range, 20–67 years), and four tumors arose in the parotid gland with one in the submandibular gland. Two of five normal salivary tissue specimens were from women. Median age at presentation was 62 years (range, 33–91 years). Three samples represented tissue excised from the submandibular gland; two were from the parotid gland.

**Expression of EN1, FABP7, MYB, and VCAN Distinguishes ACCs from Normal Tissues and Benign Tumors in the Salivary Glands**

In our search of the GEO database, we obtained gene expression profiles of 11 primary xenografted ACCs and 3 normal salivary gland
tissue samples (Accession No. GSE36820). One of the most important applications of the GEO data set to ACC pathobiology is to identify diagnostic markers [18]. To find differentially expressed genes in the data set, we compared fold changes rather than the t-statistics because we considered that larger absolute changes in gene expression would be more practical for identifying diagnostic markers [19]. We found increased expression of the following genes in primary xenografted ACC tumors: EN1, FABP7, HBE1, MYB, and VCAN. Their log2 fold changes were 6.04 (EN1), 6.01 (FABP7), 5.96 (HBE1), 5.39 (MYB), and 5.24 (VCAN), meaning that these genes increased their expression by 65.8-fold (EN1), 64.4-fold (FABP7), 62.2-fold (HBE1), 42.5-fold (MYB), and 37.8-fold (VCAN).

We then investigated whether the expression of these genes would also be elevated in sporadic ACCs from our archives. mRNA was isolated from formalin-fixed, paraffin-embedded sections as described, and qPCR was performed. Figure 1 shows that mRNA expression of EN1, FABP7, MYB, and VCAN was elevated in ACC (P < .05; Figure 1, A–D). Our probe did not detect HBE1 in these extracts. The relative expression of EN1 (increased by 848-fold over the average of normal samples) and MYB (increased by 65.8-fold over the average of normal samples) distinguished ACC from normal tissues and benign tumors (Figure 1, A and D). FABP7 mRNA in ACC was overexpressed relative to normal salivary glands (P = 2.7 × 10−10; Figure 1B), as well as BCA and PA (P = 1.1 × 10−2 and 5.0 × 10−3, respectively). VCAN’s profile was similar to EN1 and MYB, although the difference from normal salivary tissues and benign tumors was less than those in EN1 and MYB (Figure 1D).

We concluded that expression of EN1, FABP7, MYB, and VCAN distinguished ACC from normal tissues and benign salivary gland tumors.

**FABP7 Expression Is Poorly Correlated with Levels of EN1 and MYB in ACC Tumors**

To distinguish one expression profile from another in our sporadic ACCs, we determined strengths of correlation between pairs of genes in all six combinations of all genes studied. We generated scatter plots with trend lines to show correlations (Figure 2, A–F). Trend line equations and R2 values were calculated and are displayed atop each chart. Expression levels of EN1 and VCAN (Figure 2A) and EN1 and MYB (Figure 2B) were highly correlated. Their R2 values were 0.5646 and 0.224, respectively (R = 0.7514 and 0.4732). There was also a moderate correlation between MYB and VCAN (Figure 2C; R2 = 0.1533; R = 0.3915). In contrast, FABP7 expression was poorly correlated with EN1 or MYB expression (Figure 2, D and E); R2 values were 0.0035 and 0.0126, respectively (R = 0.05916 and 0.1123). FABP7 had a moderate correlation with VCAN (Figure 2F; R2 = 0.1011; R = 0.3180). Overall, FABP7 expression appeared to be regulated differently from EN1 and MYB in ACCs.

**FABP7 May Predict Poor Prognosis in Salivary ACC Patients**

To determine the biologic and prognostic significance of elevated expression of EN1, FABP7, MYB, and VCAN in ACC, we performed overall survival analysis by generating Kaplan-Meier plots with log rank testing (Figure 3, A–H). Log rank testing is a hypothesis
assessment and compares survival distributions in two samples. We divided our ACC cohort into two groups according to gene expression scores. One group had expression values above the median, and the other half's values were below it (Figure 3, A–D). We also created groups whose expression values were in the highest or lowest quartiles (Figure 3, E–H). We observed a correlation between FABP7 expression and survival (Figure 3, B and F). Specifically, the subset with the highest FABP7 gene expression (top quartile) had the poorest survival ($P = .006$). In contrast, we found no apparent correlation between survival and expression of the other genes (Figure 3, A, C–E, G, and H). These observations may explain why FABP7 expression was not strongly correlated with EN1 and MYB expression in ACC tumors (Figure 2). We concluded that FABP7 was the sole predictor of poor prognosis among the genes examined here.

**FABP7 Protein Expression in ACC Tumor Specimens**

We performed immunohistochemistry with an FABP7 antibody on normal salivary tissues and ACCs. Figure 4A shows that normal salivary glands expressed FABP7 consistently in the cytoplasm of serous acinar cells and occasionally in the nuclei of myoepithelial cells of the intercalated ducts. Moderate cytoplasmic expression was detected in epithelial cells of the intercalated and striated ducts. Figure 4B shows a cribriform subtype ACC from the patient shown in Figure 4A. FABP7 protein was predominantly found in the nucleus of myoepithelial cells and, to a lesser extent, in the cytoplasm of duct-type epithelial cells. Similar observations were made in other cribriform (Figures 4C and S1A) and tubular pattern ACC tumors (Figures 4D and S1B).

These findings agree with previous reports that ACC is biphasic, composed of duct-type epithelial and myoepithelial cells, and shows cell type–specific gene expression. For example, c-Kit and EN1 expression have been limited to duct-type epithelial cells, whereas epidermal growth factor receptor (EGFR), p63, VCAN, and MYB have been found exclusively in more differentiated myoepithelial cells [14,16,17,20–22]. Nonetheless, one cribriform case with the highest level of FABP7 mRNA (47 times normal) showed strong positive immunoreactivity in both duct-type epithelial and myoepithelial cells (Figure 4E). This observation suggests that diffuse expression of FABP7 among the two cell populations might be a factor in ACC cases with poor prognosis. Consistent with this idea, ACC cases of the solid subtype had uniform and strong positive immunoreactivity with the
FABP7 antibody (Figures 4F and S1C). These solid tumors are mostly devoid of myoepithelial cells and often associated with aggressive behavior and poor prognosis. We concluded that increased FABP7 mRNA was linked to increased protein expression and was clinically significant in ACC.

**Discussion**

Obtaining an accurate diagnosis is a major challenge for an individual who has a rare cancer [23]. It is inevitable that most physicians will only encounter individual rare diseases a few times during their careers. Unfortunately, as a result, many patients are not diagnosed until the disease has become advanced. ACC of the salivary glands is such a rare disease [1–5]. The differential diagnosis of ACC is difficult in the clinic because of the absence of unique clinical symptoms, diagnostic imaging, or microscopic features. Nonetheless, therapies and long-term outcomes are very different for ACC and other salivary neoplasms. The accurate diagnosis of ACC is essential for improving patient outcomes.

We believe that gene expression analysis can complement traditional methods of ACC diagnosis. We found that mRNA

---

**Figure 3.** FABP7 may predict poor prognosis in salivary ACC patients. (A–H) Kaplan-Meier curves showing overall survival rate of patients with sporadic ACC tumors with a higher or lower mRNA expression of EN1 (A and E), FABP7 (B and F), MYB (C and G), or VCAN gene (D and H). The ACC cohort was divided into two groups according to relative gene expression. Panels A to D compare patients with expression in the top half overall (red line) and the lower half (black line). Panels E to H compare expression in the higher quartile (red line) and lower three quartile (green line) subsets. Circles identify censored data. Statistical comparisons between data sets were made with log rank tests, and each P value is displayed. \( P < .05 \) is considered significant.
expression of EN1, FABP7, MYB, and VCAN distinguished ACC from normal tissues and benign salivary gland tumors (Figure 1). Additionally, we propose that FABP7 may be a multipurpose molecular biomarker, because its expression was correlated with poor prognosis (Figure 3). Expression of FABP7 may be useful for diagnosing ACC, predicting prognosis, and searching for more effective therapeutic options. These options may include targeting FABP7 protein itself or upstream molecules that regulate it.

FABP7 is a member of a large family of hydrophobic proteins and is expressed in the brain, heart, testis, and adipose tissues [24–26]. It binds to fatty acids and other lipids and functions as a cytoplasmic chaperone for lipid metabolism. Recent studies have found that high levels of FABP7 were also in the nucleus of glioblastoma and melanoma cells, and its expression was associated with reduced survival [27–30]. We have discovered that FABP7 protein was predominantly expressed in the nuclei of myoepithelial cells and, to a lesser extent, in the cytoplasm of duct-type epithelial cells in both tubular and cribriform subtypes of ACC (Figures 4, B–D, and S1, A and B). These findings suggest a potential role of FABP7 in the nucleus of myoepithelial cells for genesis, development, proliferation, and maintenance of ACC tumors. In contrast, the solid subtype of ACC, which is often correlated with a lower survival rate, had uniform FABP7 protein expression over the malignant cells (Figures 4F and S1C). A similar staining pattern was seen in one cribriform tumor harboring the highest levels of FABP7 mRNA and was in the lowest quartile for survival. This result suggested that diffuse expression of FABP7 protein was likely to be associated with aggressive tumor behavior and poor prognosis (Figure 4E).

FABP7 binds to docosahexaenoic acid (DHA), an omega-3 fatty acid, with the highest affinity of all FABPs [31]. In a study of U87 malignant glioma cells, DHA inhibited FABP7-mediated tumor progression by blocking the binding of arachidonic acid to FABP7 [32]. Arachidonic acid is an omega-6 fatty acid. As a result, FABP7 translocated DHA to the nucleus, where it was transferred to the peroxisome proliferator-activated receptor gamma (PPARγ) nuclear receptor and transactivated its downstream target genes, causing
attenuations of proliferation and promigratory genes. Humans naturally make small amounts of DHA but must get more from food or supplements [33].

We do not know if DHA supplementation increases risk or benefit in patients with ACC. If it inhibits FABP7-mediated tumor progression or increases health benefits in ACC similarly to the case in malignant glioma cells, DHA-rich foods such as cold water fish (e.g., salmon) or DHA supplements may benefit patients. Of course, a randomized double blind trial is necessary before such a recommendation can be made [34].

FABP7 is a Notch target gene [35,36]. Notch signaling is activated in ACC [37,38]. Recent genome-wide sequencing of ACC revealed activating mutations in genes within the Notch signaling pathway. One study performed whole exome sequencing in a series of 24 ACC tumors [37] and found two cases of missense and frameshift mutations in the NOTCH1 gene and a single case of two truncating mutations in ACC tumor-normal pairs [38]. That report demonstrated that SPEN, a negative Notch signaling regulator, had six truncating mutations in six ACC cases. Another report described the exome or whole-genome sequences of 60 signaling regulator, had six truncating mutations in six ACC cases. This report proposes FABP7 as a biomarker that can help diagnose ACC tumour-normal pairs [38]. That report demonstrated that components of the Notch signaling pathway including NOTCH1, FOXP2, DTX4, FBXW7, MAML3, and MYCN were mutated in 13% of their cohort. That report also analyzed ACC samples with altered NOTCH1 genes using a gene set enrichment analysis and showed a tendency toward enrichment of Notch signaling.

Given these findings, it is possible that FABP7 expression is regulated by the Notch signaling pathway in ACC. These results are intriguing in light of another study showing that NOTCH1 immunostaining was similar to what we observed here for FABP7 [39]. If this is the case, FABP7 may be a useful biomarker to measure response to Notch inhibitors in salivary tumors. This approach is both plausible biologically and attractive, in that Notch-targeted therapeutic antibodies are currently under clinical evaluation for other diseases [40]. This idea warrants studies addressing the links between Notch signaling and FABP7 expression in ACC.

This report proposes FABP7 as a biomarker that can help diagnose ACC, predict prognosis, and form a basis for more effective therapeutic options. Establishment of FABP7 as an ACC biomarker may aid the study of ACC in its earliest stages and will provide an opportunity to determine the contribution of normal salivary gland stem cells to the development of ACC.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.tranon.2014.10.003.

Acknowledgments
The authors gratefully acknowledge Kathryn Thompson, Jennifer Dang, Kirsten Copren, Nancy Jiang, Rick Baehner, and the UCSF Comprehensive Cancer Center Genome Analysis and Immunohistochemistry and Molecular Pathology Core Facilities for their support in TaqMan qPCR assay and immunohistochemistry.

References
[1] Spiro RH, Huvos AG, and Strong EW (1974). Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 128, 512–520.
[2] Phuchareon J, Dhruva Y, Woo JM, Eisele DW, and Tetsu O (2009). Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PLoS One 4, e6040.
[3] Tetsu O, Phuchareon J, Chou A, Cox DP, Eisele DW, and Jordan RC (2010). Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia 12, 708–717.
[4] Laurie SA and Licitra L (2006). Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24, 2673–2678.
[5] Liu J, Shao C, Tan ML, Mu D, Ferris RL, and Ha PK (2012). Molecular biology of adenoid cystic carcinoma. Head Neck 34, 1665–1677.
[6] Alberico RA, Huusain SH, and Sirokin I (2004). Imaging in head and neck oncology. Surg Oncol Clin N Am 13, 13–35.
[7] Adelstein DJ, Koyfman SA, El-Naggar AK, and Hanna EY (2012). Biology and management of salivary gland cancers. Semin Radiat Oncol 22, 245–253.
[8] Schindler S, Nayar R, Dutra J, and Bedrossian CW (2001). Diagnostisch challenges in aspiration cytology of the salivary glands. Semin Diagn Pathol 18, 124–146.
[9] Mukuyadzidzi P (2002). Review of fine-needle aspiration cytology of salivary gland neoplasms, with emphasis on differential diagnosis. Am J Clin Pathol 118, S100–S115 [Suppl.].
[10] Mino M, Pilch BZ, and Faquin WC (2003). Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod Pathol 16, 1224–1231.
[11] Sandvik AK, Alberg BK, Norset KGY, Yadeler F, Waldum Hl, and Laegreid A (2006). Gene expression analysis and clinical diagnosis. Clin Chim Acta 363, 157–164.
[12] Finn WG (2007). Diagnostic pathology and laboratory medicine in the age of "omics": a paper from the 2006 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diag 9, 431–436.
[13] Persson M, Andreen Y, Mark J, Horlings HM, Persson F, and Stenman G (2009). Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 106, 18740–18744.
[14] West RB, Kong C, Clarke N, Gilks T, Lipstick JS, Cao H, Kwik S, Montgomery KD, Varma S, and Le QT (2011). MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 35, 92–99.
[15] Frierson Jr HF, El-Naggar AK, Welsh JH, Sapinono LM, Su AI, Cheng J, Saku T, Moskaluk CA, and Hampton GM (2002). Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol 161, 1315–1323.
[16] Bell D, Bell A, Roberts D, Weber RS, and El-Naggar AK (2012). Developmental transcription factor EN1—a novel biomarker in human salivary gland adenoid cystic carcinoma. Cancer 118, 1288–1292.
[17] Moskaluk CA, Baras AS, Mancuso SA, Fan H, Davidson RJ, Dirks DC, Golden WL, and Frierson Jr HF (2011). Development and characterization of xenograft model systems for adenoid cystic carcinoma. Lab Invest 91, 1480–1490.
[18] Shi X, Shen S, Liu J, Huang J, Zhou Y, and Ma S (2013). Similarity of markers identified from cancer gene expression studies: observations from GEO. Brief Bioinform 15, 671–684.
[19] Jeffery IB, Higgins DG, and Culhane AC (2006). Comparison and evaluation of methods for generating differentially expressed gene lists from microarray data. BMC Bioinformatics 7, 559.
[20] Bell D, Roberts D, Kies M, Rao P, Weber RS, and El-Naggar AK (2010). Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications. Cancer 116, 5749–5756.
[21] Edwards PC, Bhuity T, and Kelsch RD (2004). Assessment of p63 expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and basal cell and canalicul adenomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97, 613–619.
[22] Cheuk W and Chan JK (2007). Advances in salivary gland pathology. Histopathology 51, 1–20.
[23] Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Strojan P, Licitra L, and RARECARE Working Group (2012). Rare cancers of the head and neck area in Europe. Eur J Cancer 48, 783–796.
[24] Feng L and Heintz N (1995). Differentiating neurons activate transcription of the brain lipid-binding protein gene in radial glia through a novel regulatory element. Development 121, 1719–1730.
[25] Shimizu F, Watanabe TK, Shimitoya H, Nakamura Y, and Fujiwara T (1997). Isolation and expression of a cDNA for human brain fatty acid-binding protein (B-FABP). Biochim Biophys Acta 1354, 24–28.
[26] Heath J and Thurner AE (2010). Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem 285, 32679–32683.
[27] Liang Y, Dinh M, Watson N, Bollon AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, and Brown PO, et al (2005). Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 102, 5814–5819.
Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K, Murata H, Takata M, Aburatani H, and Hoon DS, et al (2006). A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res 66, 4443–4449.

Slipicevic A, Jorgensen K, Skrede M, Rosnes AK, Troen G, Davidson B, and Florenes VA (2008). The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer 8, 276.

Goto Y, Koyanagi K, Narita N, Kawakami Y, Takata M, Uchiyama A, Nguyen L, Nguyen T, Ye X, and Morton DL, et al (2010). Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. J Invest Dermatol 130, 221–229.

Xu LZ, Sánchez R, Sali A, and Heintz N (1996). Ligand specificity of brain lipid-binding protein. J Biol Chem 271, 24711–24719.

Mita R, Beaulieu MJ, Field C, and Godbout R (2010). Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: mechanistic insight into malignant glioma cell migration. J Biol Chem 285, 37005–37015.

Horrocks LA and Yeo YK (1999). Health benefits of docosahexaenoic acid (DHA). Pharmacol Res 40, 211–225.

Merendino N, Costantini L, Manzi L, Molinari R, D’Eliseo D, and Velotti F (2013). Dietary ω-3 polyunsaturated fatty acid DHA: a potential adjuvant in the treatment of cancer. Biomed Res Int 2013, 310186. doi: 10.1155/2013/310186.

Anthony TE, Mason HA, Gridley T, Fishell G, and Heintz N (2005). Brain lipid-binding protein is a direct target of Notch signaling in radial glial cells. Genes Dev 19, 1028–1033.

Bray SJ (2006). Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 7, 678–689.

Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, Papaemmanuil E, Cheverton A, Bignell GR, and Butler AP, et al (2013). Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest 123, 2965–2968.

Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, and Huse JT, et al (2013). The mutational landscape of adenoid cystic carcinoma. Nat Genet 45, 791–798.

Bell D, Hanna EY, Miele L, Roberts D, Weber RS, and El-Naggar AK (2014). Expression and significance of notch signaling pathway in salivary adenoid cystic carcinoma. Ann Diagn Pathol 18, 10–13.

Wu Y, Cain-Horn C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D, Venook R, Wu X, and Ridgway J, et al (2010). Therapeutic antibody targeting of individual Notch receptors. Nature 464, 1052–1057.